Vaxcyte PCVX 深 滬
已收盤 02-06 16:00:00 美东时间
56.15
+2.240
+4.16%
華盛通- 最 高56.45
- 今 開55.16
- 成交量 108.08万股
- 最 低 54.32
- 昨 收 53.91
- 總市值 80.61亿
- 52周最高 85.22
- 市盈率 靜 --
- 換手率 0.75%
- 52周最低 27.66
- 委 比 -88.28%
- 總股本 1.44亿
- 歷史最高 121.055
- 量 比 0.32
- 振 幅 3.95%
- 歷史最低 15.51
- 每 手 1
- 風險率 15.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
An update from Vaxcyte ( ($PCVX) ) is now available. On January 29, 2026, Vaxcy...
02-03 05:43
Vaxcyte nimmt durch Aktienemission 600 Millionen Dollar ein
Vaxcyte nimmt durch Aktienemission 600 Millionen Dollar ein Vaxcyte Inc. hat eine Folgeemission durchgeführt und insgesamt 12.650.000 neue Stammaktien erfolgreich platziert. Das Unternehmen erzielte dabei einen Nettoerlös von rund 600,2 Millionen US-Dollar. Die Aktien wurden zu einem Preis von 50,00
02-03 05:02
Guggenheim Reiterates Buy on Vaxcyte, Maintains $116 Price Target
Guggenheim analyst Seamus Fernandez reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $116 price target.
02-02 22:34
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
BUZZ-Vaxcyte edges higher after upsized $550 mln equity raise
BUZZ-Vaxcyte edges higher after upsized $550 mln equity raise ** Pneumococcal vaccine developer Vaxcyte PCVX.O shares up 0.8% to $53.24 premarket after above-target $550 mln equity raise ** San Carlos, California-based firm late Thurs sold 11 mln shares at $50 ** Offering size boosted from $ 500 mln
01-30 22:00
Vaxcyte launches proposed $500M public offering of stock, warrants
Vaxcyte (PCVX) on Thursday said that it has commenced an underwritten public offering of $500 million of common stock and pre-funded warrants. The clinical-stage vaccine developer said all securities ...
01-30 05:20
Vaxcyte Launches $500M Common Stock, Pre-Funded Warrants Offering
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants. All shares of
01-30 05:18
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte, Inc. announced an underwritten public offering of 11 million shares of common stock at $50 per share, raising $550 million. An additional 1.65 million shares may be purchased by underwriters within 30 days. The offering is expected to close on February 2, 2026. BofA Securities, Jefferies, and others are acting as book-running managers and co-managers. The securities are registered with the SEC, and a final prospectus supplement will be a...
01-30 04:33
Vaxcyte Advances VAX-31 Program With First Dosing In Adult Phase 3 OPUS-2 Trial; Plans Additional Phase 3 OPUS-3 Study In 2026; Completes Infant Phase 2 Enrollment
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults
01-23 06:07
